McGill IBD logo
Donate

Abbvie | Protocol M16-067

Molecule: Risakizumab-anti-IL23-IV Induction


Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy.

 

Abbvie  | Protocol M16-066

Risakizumab-anti-IL23-SC maintenance & OLE


Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065.

 

Eli Lily | Protocol I6T-MC-AMBG

Molecule: mirikizumab-anti-IL23- SC maintenance +/- IV rescue dose


Study Title:
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.

 

Eli Lily | Protocol I6T-MC-AMAP

Long Term extension study for I6T-MC-AMBG and I6T-MC-AMAC


Study Title:
A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.

 

Protocol APD334-302 (Pending REB Approval)

Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)


Study Title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

 

Arena | Protocol APD334-303 (Pending REB Approval)

Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)


Study Title:

An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis.

 

Arena/ Protocol APD334-210 (Pending REB Approval)


Study Title: A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis

Your donations contribute to the delivery of specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.

Donate